Terms & Conditions


- - -  Products  - - -










Testron SX


ProDHEA Cream


Melatonine Cream


ProGen Cream


-  Information  -


Benefits of DHEA


DHEA History


Melatonin Update


Customers Comments


Medical Testimonials





The majority of clinical trials investigating the effect of DHEA on weight or fat loss, as well as on obesity, support its use for this purpose.

Metabolic Syndrome

Metabolic Syndrome is characterized by several conditions that are all associated with elevated risk for heart disease, including increased insulin resistance, obesity, and abnormal cholesterol levels. In metabolic syndrome, these individual risk factors act synergistically, raising the risk of heart disease higher than their individual risk levels alone. Although research is still continuing, scientists have linked elevated cholesterol to lower DHEA levels. Long-term DHEA supplementation improves insulin sensitivity by 30%, raises high-density lipoprotein cholesterol by 12%, and lowers low-density lipoprotein cholesterol by 11% and triglycerides by 20%. The lowering of low density lipoproteins (LDL) by DHEA has an antioxidant effect, which could have
anti-atherogenic consequences. DHEA also decreases abdominal fat, an important characteristic of metabolic syndrome.


Clinical Studies

  • The P. Diamond group of Quebec, Canada performed a 12 month study with 15 60-70 year old women, using a 10% DHEA cream applied to the skin. A 3.8% increase (P< 0.05) in femoral fat and a 3.5% increase (P < 0.05) in femoral muscular areas were observed at 12 months.  These changes in body fat and muscular mass were associated with a 11% decrease (P < 0.05) in fasting plasma glucose and a 17% decrease (P < 0.05) in fasting insulin levels.

  • A randomized, double-blind, placebo-controlled trial conducted in a US university-based research centre (Washington University School of Medicine) from June 2001 to February 2004. Participants: Fifty-six elderly persons (28 women and 28 men aged 71 years; range, 65-78 years) with age-related decrease in DHEA level. Participants were randomly assigned to receive 50 mg/day of DHEA or matching placebo for six months. The primary outcome measures were six-month change in visceral and subcutaneous abdominal fat measured by magnetic resonance imaging and glucose and insulin responses to an oral glucose tolerance test (OGTT). Of the 56 men and women enrolled, 52 underwent follow-up evaluations. Compliance with the intervention was 97% in the DHEA group and 95% in the placebo group. Based on intention-to-treat analyses, DHEA therapy compared with placebo induced significant decreases in visceral fat area
    (-13 cm2 vs. +3 cm2, respectively; P=0.001) and subcutaneous fat (-13 cm2 vs. +2 cm2, P=0.003). The insulin area under the curve (AUC) during the OGTT was significantly reduced after six months of DHEA therapy compared with placebo (-1119 µU/ml per 2 h vs. +818 µU/ml per 2 h, P=0.007). Despite the lower insulin levels, the glucose AUC was unchanged, resulting in a significant increase in an insulin sensitivity index in response to DHEA compared with placebo (+1.4 vs. -0.7, P=0.005). DHEA replacement could play a role in prevention and treatment of the metabolic syndrome associated with abdominal obesity.








  Copyright 2001- 2018 © DHEAUSA.COM   All rights reserved.